Advertisement
UK markets close in 1 hour

  • FTSE 100

    7,862.87
    -14.18 (-0.18%)
     

  • FTSE 250

    19,340.46
    -110.21 (-0.57%)
     

  • AIM

    744.06
    -1.23 (-0.17%)
     

  • GBP/EUR

    1.1666
    -0.0017 (-0.15%)
     

  • GBP/USD

    1.2459
    +0.0021 (+0.17%)
     

  • Bitcoin GBP

    51,402.12
    +181.75 (+0.35%)
     

  • CMC Crypto 200

    1,376.41
    +63.78 (+5.11%)
     

  • S&P 500

    5,000.62
    -10.50 (-0.21%)
     

  • DOW

    37,961.88
    +186.50 (+0.49%)
     

  • CRUDE OIL

    82.97
    +0.24 (+0.29%)
     

  • GOLD FUTURES

    2,404.60
    +6.60 (+0.28%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,739.30
    -98.10 (-0.55%)
     

  • CAC 40

    8,028.02
    +4.76 (+0.06%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

DBV Technologies S.A.
·1-min read
DBV Technologies S.A.
DBV Technologies S.A.

Montrouge, France, June 16, 2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York.

A webcast of the presentation will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

ADVERTISEMENT

A replay of the presentation will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com

Attachment